At present, retatrutide does not hold a marketing authorisation in the UK, the European Union, or the United States
Know that before you enroll
More broadly, any product marketed for weight loss may create delays in proper diagnosis or treatment if a person relies on it instead of seeking medical care for obesity, insulin resistance, or diabetes
(5) Considering a low number of expected cases could lead to an insufficient sensitivity to detect disproportionality of relevant strength [31], we reported the sensitivity of a representative IC 025 to measure the reliability of negative results
Until approval, retatrutide is unavailable for general use, and any compounded versions see heavy regulatory oversight
The Timeline Results begin to show rapidly